MIT assistant professor alleges Sabatini 'coerced' her into sex, led 'highly sexualized lab' Merck KGaA steps up VC activity with $677M investment, positioning M Ventures to keep pace with changing landscape 'Day job and a gay job': LGBTQ+ leaders in biopharma want those who look, talk and love like them to be seen and counted Newpath en route to backing a host of biotechs with $350M 2nd fund Fresh from $316M raise, Sotio inks Merck deal for Keytruda combo trial Corbus poaches Takeda's oncology leader as it beefs up early-stage pipeline following 3 trial failures OncoMyx nabs $50M to jump into the clinic with its rabbit pox virus cancer drug Avistone nabs $200M cancer platform funding drive from leading VCs as it combines with Pearl Biotech Former FDA head Hahn takes helm of cancer blood test maker Harbinger Health Shkreli's former company Vyera settles for $40M in antitrust case, but 'pharma bro' still faces his own trial Science 37's biopharma clients can test treatments in China, Russia months after expansion into Japan Featured Story | By Kyle LaHucik In a counterclaim filing against MIT professor David Sabatini, his former mentee and Whitehead Institute colleague alleges he "coerced" her into sex and led a "highly sexualized" lab. She claimed his October filing, in which he alleged he was the victim, was a "frivolous lawsuit" riddled with conspiracies. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Merck KGaA is upping its commitment to corporate venture capital with a 600 million euro ($677 million) investment, positioning its VC arm M Ventures to up the number and size of its bets over the next five years. read more By Kyle LaHucik Organizations for LGBTQ+ biopharma employees are popping up in Boston, San Francisco, New York, New Jersey, Dublin and elsewhere. Companies are also working to build up their internal networks as LGBTQ+ employees want to see those who look, talk and love like them. read more By Kyle LaHucik Newpath will dole out the $350 million fund to bankroll startups from academic partners at Scripps, Harvard Medical School, Broad Institute, Columbia University and elsewhere. The venture shop will back up to another dozen biotechs after funding Chroma Medicine, Kojin Therapeutics and others. read more By Nick Paul Taylor Sotio Biotech has advanced its effort to become a major player in the solid tumor space. Days after raising $316 million, Sotio has unveiled a deal with Merck to use Keytruda in a clinical trial that is central to its plans for investing in the megaround. read more By Kyle LaHucik With multiple mid- and late-stage failures of its only clinical-stage compound, Corbus Pharmaceuticals is attempting to move forward with earlier-stage assets it in-licensed this summer. So the biopharma hired Takeda oncology leader Rachael Brake as chief scientific officer to lead those efforts. read more By Ben Adams In April, startup OncoMyx published some very early preclinical models showing its engineered rabbit pox virus could help against lung cancer; now, it's got off a $50 million funding round to take its big idea into the clinic. read more By Ben Adams Vivo Capital, Bain Capital and Primavera Capital have all come together to place a $200 million-plus bet on lung cancer startup Avistone Pharmaceuticals as it looks to join forces with fellow oncology company Pearl Biotechnology. read more By Andrea Park Similar to the technology being developed by fellow cancer-focused liquid biopsy developers Grail and Freenome, Harbinger’s platform will use machine learning and other artificial intelligence software to analyze a standard blood sample to detect biological indicators of cancer before symptoms arise. read more By Fraiser Kansteiner Vyera Pharmaceuticals has agreed to pay up to $40 million to settle charges that it engaged in anticompetitive practices to ward off generics and maintain “monopoly profits” from its more than 4,000% overnight price hike on the toxoplasmosis med Daraprim. read more By Kyle LaHucik With more resources in hand following its October Nasdaq listing, Science 37 has beefed up its presence in the Asia-Pacific region. The latest move sees the hybrid trials provider enter China and Russia. read more Resources Sponsored by: WIRB - Copernicus Group Sites receiving augmentation support enroll more than 30,000 patients in just over three months. See how additional site resources can make a difference. Sponsored By: BBK Worldwide Create more inclusive clinical trials, enroll them faster, and keep participants engaged longer with the latest Study Voices survey results and insights. Sponsored by: GLG A major Korean biopharmaceutical company wanted to gather unbiased opinions on a new cancer treatment product. Fill out our form to learn more. Sponsored by: GLG Download now to learn how GLG helped a biotech company plan for the demand of a new drug/device combination by commissioning a forecasting study. Sponsored by: Thermo Fisher Scientific A variety of genetic analysis methods are valuable in ensuring that ex vivo human cells to be used for cell-based therapies are correctly identified, have the correct characteristics, and are free of contaminants. Sponsored by: Thermo Fisher Scientific Learn how a CDMO partnered with Thermo Fisher Scientific to manage high-volume process liquid and buffer preparation scale-up. Download the free case study from Thermo Fisher Scientific Sponsored by: Clario This whitepaper addresses where AI can make the biggest impact in clinical trials. The stakes are too high for patients to leave decision-making to machines, but AI can lend administrative support that empowers staff and medical experts alike to carry out their jobs more effectively. Sponsored by: Medable, Inc. Find out how to improve clinical protocol adherence, and thus patient outcomes, by 15%+ with Medable’s latest White Paper. Sponsored by: IQVIA Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making. Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Informa Pharma Intelligence and Oracle Health Sciences New market research provides valuable insight into the impact of adaptations made in clinical trials during the pandemic. Sponsored by: Thermo Fisher Scientific Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Fierce Virtual Clinical Trials Summit December 6-7, 2021 | Philadelphia, PA Fierce JPM Week 2022 January 11, 2022 | San Francisco, CA
January 18-20, 2022 | Virtual Event Fierce Drug Safety Summit February 8-9, 2022 | Arlington, VA Fierce Business Development and Licensing Summit March 2022 | San Francisco, CA Fierce Promotional Review Committee Compliance and Best Practices Summit April 12-14, 2022 | New Brunswick, NJ Fierce Medical Affairs Strategic Summit (MASS) East April 12-14, 2022 | New Brunswick, NJ Fierce Health IT Summit April 20, 2022 | Virtual Event Fierce Trial Master File Summit May 2022 | Location TBD Fierce Digital Pharma Innovation Week June 2022 | Virtual Event Fierce Biotech Next-Gen June 29, 2022 | Virtual Event Fierce Pharma PR & Communications Summit July 2022 | Location TBD (NYC Metro Area) Fierce Biotech Forum October 2022 | Location TBD Fierce Biotech Virtual Forum October 19, 2022 | Virtual Event | 